Podimetrics is a passive patient monitoring platform focused on identifying early signs of inflammation and diabetic foot ulcers (DFU). Its flagship product is the FDA-approved SmartMat which uses machine learning and customized thermograms to analyze and support clinical decisions. Patients step on the smart mat for 20 seconds to record temperature changes in the foot and the readings are remotely monitored by the firm’s nurse support team, which connects patients with their healthcare providers if a health issue is flagged. The device is capable of detecting warning signs of DFU up to five weeks before they can be clinically diagnosed.
The company’s SmartMat also received approval from the American Podiatric Medical Association.
Key customers and partnerships
It operates a B2B2C model via partnerships with risk-based healthcare providers and health plans such as the Veterans Health Administration and Independence Blue Cross.
Funding and financials
In November 2022, Podimetrics secured USD 25 million in debt financing from CIBC Innovation Banking. Prior to that, the company concluded a USD 45 million Series C funding round led by D1 Capital Partners. The funds were used for commercial operations.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.